Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Concepción Herrera Arroyo"'
Autor:
José Suárez de Lezo Cruz Conde, Manuel Pan Álvarez-Ossorio, Miguel Ángel Romero Moreno, Concepción Herrera Arroyo, Flor Baeza Garzón, Vanesa Martín Palanco
Publikováno v:
Revista Española de Cardiología (English Edition). 71:344-350
Introduction and objectives Bone marrow stem cells may reconstruct infarcted myocardium through distinct mechanisms. However, little is known on the relationship between recovery of muscular and microvascular function after regenerative treatments. O
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5885698c1048f0ab9ac8e77c695eb674
https://doi.org/10.1016/j.rec.2017.07.018
https://doi.org/10.1016/j.rec.2017.07.018
Autor:
Concepción Herrera Arroyo, José Suárez de Lezo Cruz Conde, Manuel Pan Álvarez-Ossorio, Miguel Ángel Romero Moreno, Flor Baeza Garzón, Vanesa Martín Palanco
Publikováno v:
Revista Española de Cardiología. 71:344-350
Resumen Introduccion y objetivos Las celulas madre de medula osea pueden regenerar el miocardio infartado por distintos mecanismos. La relacion entre la recuperacion de la funcion muscular y microvascular despues del tratamiento regenerativo ha sido
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bddba52dc5c4d2a49391a92312909ae9
https://doi.org/10.1016/j.recesp.2017.07.012
https://doi.org/10.1016/j.recesp.2017.07.012
Autor:
Flor, Baeza Garzón, Manuel, Pan Álvarez-Ossorio, Miguel Ángel, Romero Moreno, Vanesa, Martín Palanco, Concepción, Herrera Arroyo, José, Suárez de Lezo Cruz Conde
Publikováno v:
Revista espanola de cardiologia (English ed.). 71(5)
There is little evidence on the optimal strategy for bifurcation lesions in the context of a coronary chronic total occlusion (CTO). This study compared the procedural and mid-term outcomes of patients with bifurcation lesions in CTO treated with pro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::34f39c4c10307fb6a04392d61c982191
https://pubmed.ncbi.nlm.nih.gov/29097079
https://pubmed.ncbi.nlm.nih.gov/29097079
Autor:
Mohamed A. Kharfan-Dabaja, Myriam Labopin, Ernesto Ayala, Ali Bazarbachi, Didier Blaise, Jan Vydra, Stefania Bramanti, Maija Itälä-Remes, Christoph Schmid, Alessandro Busca, Edouard Forcade, Werner Rabitsch, Marco Zecca, Nicolaus Kröger, Claude-Eric Bulabois, Giovanni Grillo, Alessandro Rambaldi, Renato Fanin, Francesco Zallio, Nicola Di Renzo, Yener Koc, Yana Novis, Andrew McDonald, Concepcion Herrera Arroyo, Jaime Sanz, Arnon Nagler, Fabio Ciceri, Mohamad Mohty
Publikováno v:
HemaSphere, Vol 7, Iss 7, p e920 (2023)
Availability of haploidentical donors has broadened utilization of allogeneic hematopoietic cell transplantation (allo-HCT). Peripheral blood stem cells (PBSC) are being used with increased frequency in haploidentical allo-HCT. We evaluated extent of
Externí odkaz:
https://doaj.org/article/a86fb26892d24374b8fde8eaa22d0625
Autor:
Sjoerd J. F. Hermans, Jurjen Versluis, Myriam Labopin, Sebastian Giebel, Yvette van Norden, Ivan Moiseev, Didier Blaise, Jose L. Díez Martín, Ellen Meijer, Montserrat Rovira, Goda Choi, Anna Maria Raiola, Yener Koc, Péter Reményi, Jan Vydra, Nicolaus Kröger, Simona Sica, Massimo Martino, Gwendolyn van Gorkom, Patrice Chevallier, Alessandro Busca, Concepcion Herrera Arroyo, Eolia Brissot, Zinaida Peric, Arnon Nagler, Roni Shouval, Fabio Ciceri, Jan J. Cornelissen, Mohamad Mohty
Publikováno v:
HemaSphere, Vol 7, Iss 3, p e846 (2023)
Graft versus host disease (GVHD) prophylaxis with posttransplantation cyclophosphamide (PTCY) has been established to reduce severe GVHD, and thereby potentially reducing nonrelapse mortality (NRM) after allogeneic stem cell transplantation (alloSCT)
Externí odkaz:
https://doaj.org/article/f3ecf1ce04e04a398237df8bf608faa2
Autor:
Marie Robin, Raphael Porcher, Fabio Ciceri, Maria Teresa van Lint, Stella Santarone, Gerhard Ehninger, Didier Blaise, Zafer Güllbas, Soledad Gonzáles Muñiz, Mauricette Michallet, Andrea Velardi, Linda Koster, Johan Maertens, Jorge Sierra, Dominik Selleslag, Aleksandar Radujkovic, José L. Díez-Martin, Lothar Kanz, Concepcion Herrera Arroyo, Dietger Niederwieser, He Huang, Andrew McDonald, Theo de Witte, Yener Koc, Nicolaus Kröger
Publikováno v:
Blood Advances, Vol 1, Iss 22, Pp 1876-1883 (2017)
Abstract: The only curative treatment in patients with intermediate or high-risk myelodysplastic syndrome (MDS) is allogeneic hematopoietic stem cell transplantation (HSCT), which usually results in a long-term, disease-free survival rate of between
Externí odkaz:
https://doaj.org/article/e80a39776634444ab9d29e2f482ecea6